|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0205396,
umls-concept:C0536940,
umls-concept:C0871261,
umls-concept:C1332714,
umls-concept:C1413787,
umls-concept:C1519885,
umls-concept:C1522673,
umls-concept:C1529741,
umls-concept:C1704632,
umls-concept:C1704858,
umls-concept:C1706817,
umls-concept:C2825965,
umls-concept:C2911692
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2004-6-23
|
|
pubmed:abstractText |
There is increasing evidence showing the involvement of CD4(+) T cells in initiating and maintaining antitumor immune responses. NY-ESO-1 is expressed by various tumors but not normal tissues except testis. We conducted a cancer clinical trial by using full-length NY-ESO-1 protein formulated with ISCOMATRIX adjuvant and injected into patients intramuscularly. Autologous dendritic cells pulsed with NY-ESO-1 ISCOMATRIX in combination with overlapping synthetic peptides were used to identify immunodominant T cells from a vaccinated patient. We show here the identification and characterization of two novel CD4(+) T cell epitopes. T cells specific to these epitopes not only recognized autologous dendritic cells loaded with NY-ESO-1 but also NY-ESO-1-expressing tumor cell lines treated with IFN-gamma. One of the two responses identified was greater than the previously identified immunodominant HLA-DP4-restricted response and correlated with NY-ESO-1-specific CD8(+) T cell induction after vaccination. This T cell response was vaccinated in most patients who expressed HLA-DR2. This study has systematically surveyed patients vaccinated with full-length tumor antigen for a vaccinated CD4 helper T cell response.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-10388649,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-10684854,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-10781081,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-10878392,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-11259659,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-11315507,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-12097265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-12133998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-12438231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-12525559,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-12594515,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-12727928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-12853579,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-1314884,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-2137372,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-3494718,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-8760829,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-9064346,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-9432985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15197261-9624004
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
pubmed-author:CebonJonathanJ,
pubmed-author:ChenQiyuanQ,
pubmed-author:ChenWeisanW,
pubmed-author:DavisIan DID,
pubmed-author:DimopoulosNektariaN,
pubmed-author:GoldieHeatherH,
pubmed-author:GreenSimonS,
pubmed-author:HopkinsWendieW,
pubmed-author:JacksonHeatherH,
pubmed-author:LukeTinaT,
pubmed-author:MaraskovskyEugeneE,
pubmed-author:MastermanKelly-AnneKA,
pubmed-author:McCluskeyJamesJ,
pubmed-author:MifsudNicole ANA,
pubmed-author:MiloradovicLenaL,
pubmed-author:OldLloyd JLJ,
pubmed-author:ParentePhillipP,
pubmed-author:RizkallaMarkM,
pubmed-author:TaiTsin YeeTY,
pubmed-author:ZhuHe-ChengHC
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
22
|
|
pubmed:volume |
101
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
9363-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15197261-Amino Acid Sequence,
pubmed-meshheading:15197261-Antigens, Neoplasm,
pubmed-meshheading:15197261-CD4-Positive T-Lymphocytes,
pubmed-meshheading:15197261-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15197261-Cell Line, Tumor,
pubmed-meshheading:15197261-Cells, Cultured,
pubmed-meshheading:15197261-Epitopes,
pubmed-meshheading:15197261-Humans,
pubmed-meshheading:15197261-Lymphocyte Activation,
pubmed-meshheading:15197261-Major Histocompatibility Complex,
pubmed-meshheading:15197261-Male,
pubmed-meshheading:15197261-Membrane Proteins,
pubmed-meshheading:15197261-Molecular Sequence Data,
pubmed-meshheading:15197261-Testis,
pubmed-meshheading:15197261-Vaccines, Synthetic
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant.
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, Austin Health, 145-163 Studley Road, Heidelberg, Victoria 3084, Australia.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
